Marcus Vinícius Magno Gonçalves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marcus Vinícius Magno Gonçalves has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- André Matta
Ventus Therapeutics U.S., Inc. Waltham Massachusetts USA
1 shared publication - Beatriz Sordi Chara
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication - Clara Sasse Scherer
Universidade da Região de Joinville, Departamento de Medicina, Joinville SC, Brazil
1 shared publication Isabelle Pastor Bandeira
Department of Medicine, Universidade da Região de Joinville (UNIVILLE), Santa Catarina, Brazil
1 shared publicationLaura Fiuza Parolin
Department of Neurology, Universidade da Região de Joinville (UNIVILLE), Santa Catarina, Brazil
1 shared publicationLeticia Caroline Breis
Department of Medicine, Universidade da Região de Joinville (UNIVILLE), Santa Catarina, Brazil
1 shared publication
Latest Publications
- Open Access
- 23 February 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (03) , 1-10
Impacts of environmental tobacco smoke on the onset and progression of multiple sclerosis: a systematic review
Background Unlike cigarette smoking, environmental tobacco smoke (ETS) has not been as well described as an environmental risk for Multiple sclerosis (MS) nor as a risk factor for disease progression. Objective We systematically reviewed the association between ETS and the risk of onset and/or progression of MS. Methods We systematically screened MedLine/PubMed, Science Direct, LILACs, and SciELO searching for publications between January 1st, 2010, and July 5, 2021, with the following keywords: “multiple sclerosis and smoking”; “multiple sclerosis and passive smoking”; “multiple sclerosis and secondhand smoking”. Results Fifteen articles were included in this review, which consisted of systematic reviews with meta-analysis (N = 2), systematic reviews (N = 2), and observational studies (N = 11). Both meta-analyses reported an impact of ETS on MS onset among secondhand smokers. One of the systematic reviews selected two observational studies showing the association between ETS and MS development, and one study that did not find a significant association between ETS and the risk of MS development. The other systematic review identified selected eight articles showing a relationship between ETS and MS. Seven observational studies reported higher odds of MS onset when associated with ETS. Four observational studies did not show a relationship between ETS and MS onset or progression. Conclusion Most articles showed a positive association between ETS exposure and the risk of developing MS. On the other hand, an association between ETS and a higher risk for MS progression could not be established.
- 23 February 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (03) , 1-10
Open AccessImpacts of environmental tobacco smoke on the onset and progression of multiple sclerosis: a systematic review
Background Unlike cigarette smoking, environmental tobacco smoke (ETS) has not been as well described as an environmental risk for Multiple sclerosis (MS) nor as a risk factor for disease progression. Objective We systematically reviewed the association between ETS and the risk of onset and/or progression of MS. Methods We systematically screened MedLine/PubMed, Science Direct, LILACs, and SciELO searching for publications between January 1st, 2010, and July 5, 2021, with the following keywords: “multiple sclerosis and smoking”; “multiple sclerosis and passive smoking”; “multiple sclerosis and secondhand smoking”. Results Fifteen articles were included in this review, which consisted of systematic reviews with meta-analysis (N = 2), systematic reviews (N = 2), and observational studies (N = 11). Both meta-analyses reported an impact of ETS on MS onset among secondhand smokers. One of the systematic reviews selected two observational studies showing the association between ETS and MS development, and one study that did not find a significant association between ETS and the risk of MS development. The other systematic review identified selected eight articles showing a relationship between ETS and MS. Seven observational studies reported higher odds of MS onset when associated with ETS. Four observational studies did not show a relationship between ETS and MS onset or progression. Conclusion Most articles showed a positive association between ETS exposure and the risk of developing MS. On the other hand, an association between ETS and a higher risk for MS progression could not be established.
- 8 December 2020
- Published by SAGE Publications in Lupus
- Vol. 30 (3) , 385-392
MOG-IgG-associated disorder and systemic lupus erythematosus disease: Systematic review
Introduction: Myelin oligodendrocyte glycoprotein (MOG) is a nervous system protein expressed by oligodendrocytes to constitute the myelin sheath. Autoantibodies against MOG have been widely described in neurological and autoimmune diseases such as MOG-IgG-associated disorder (MOGAD). Although underlying mechanisms have not yet been understood, an overlap of MOGAD and Systemic Lupus Erythematosus (SLE) has been shown in the literature. Objectives: The aim of this systematic review was to assess the possible correlations between MOGAD and SLE based on reported features found in the literature that support the association of the two. Methods: A keyword-based literature search was conducted, applying a ten-year filter and using the following key-words: “MOG autoantibody-associated disease and Systemic Lupus Erythematosus”; “MOG and Systemic Lupus Erythematosus” “Anti-MOG and Lupus”; “MOG and SLE”; “MOG and LUPUS” on MEDLINE/PUBMED, ScienceDirect, SciELO, LILACS and Cochrane; and “MOG antibody-associated disease and SLE” on Google Scholar. Results: Eleven publications reporting on the MOGAD and SLE correlation were included in qualitative synthesis: animal experiment (1), cross-sectional (3), prospective (2), retrospective (1), non-systematic review (3), and case report (1) studies. Conclusion: Not much is known about the connection between MOG-IgG-associated disorder and SLE. Unfortunately, only observational studies have been conducted in humans so far, providing us with limited data. While MOGAD features have been reported to develop in SLE patients, this is not an universal finding. In fact, many different issues impair these results, making it difficult to match the findings of different studies.
- 8 December 2020
- Published by SAGE Publications in Lupus
- Vol. 30 (3) , 385-392
MOG-IgG-associated disorder and systemic lupus erythematosus disease: Systematic review
Introduction: Myelin oligodendrocyte glycoprotein (MOG) is a nervous system protein expressed by oligodendrocytes to constitute the myelin sheath. Autoantibodies against MOG have been widely described in neurological and autoimmune diseases such as MOG-IgG-associated disorder (MOGAD). Although underlying mechanisms have not yet been understood, an overlap of MOGAD and Systemic Lupus Erythematosus (SLE) has been shown in the literature. Objectives: The aim of this systematic review was to assess the possible correlations between MOGAD and SLE based on reported features found in the literature that support the association of the two. Methods: A keyword-based literature search was conducted, applying a ten-year filter and using the following key-words: “MOG autoantibody-associated disease and Systemic Lupus Erythematosus”; “MOG and Systemic Lupus Erythematosus” “Anti-MOG and Lupus”; “MOG and SLE”; “MOG and LUPUS” on MEDLINE/PUBMED, ScienceDirect, SciELO, LILACS and Cochrane; and “MOG antibody-associated disease and SLE” on Google Scholar. Results: Eleven publications reporting on the MOGAD and SLE correlation were included in qualitative synthesis: animal experiment (1), cross-sectional (3), prospective (2), retrospective (1), non-systematic review (3), and case report (1) studies. Conclusion: Not much is known about the connection between MOG-IgG-associated disorder and SLE. Unfortunately, only observational studies have been conducted in humans so far, providing us with limited data. While MOGAD features have been reported to develop in SLE patients, this is not an universal finding. In fact, many different issues impair these results, making it difficult to match the findings of different studies.